Categories: NewsPharmaceutical

89bio to Participate in the H.C. Wainwright 6th Annual NASH Investor Conference

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

SAN FRANCISCO, Oct. 13, 2022 (GLOBE NEWSWIRE) — 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced that Company’s Management will participate in a fireside chat and one-on-one investor meetings at the H.C. Wainwright 6th Annual NASH Investor Conference on Monday, October 17, 2022 at 11:30 AM ET.

The webcast of the presentation will be accessible here and in the investor section of 89bio’s website.

About 89bio 
89bio is a clinical-stage biopharmaceutical company dedicated to the development of best-in-class therapies for patients with liver and cardiometabolic diseases who lack optimal treatment options. The company is focused on rapidly advancing its lead candidate, pegozafermin, through clinical development for the treatment of non-alcoholic steatohepatitis (NASH) and severe hypertriglyceridemia (SHTG). Pegozafermin is a specifically engineered, potentially best-in-class fibroblast growth factor 21 (FGF21) analog with unique glycoPEGylated technology that optimizes biological activity through an extended half-life. The company is headquartered in San Francisco with operations in Herzliya, Israel. For more information, visit www.89bio.com or follow the company on LinkedIn.

Investor Contact: 
Ryan Martins 
Chief Financial Officer 
investors@89bio.com

Media Contact: 
Lauren Barbiero
Real Chemistry
lbarbiero@realchemistry.com

 

Staff

Recent Posts

CORRECTING and REPLACING Vouched Developing Integration in Epic Toolbox Under Construction for Remote Identity Verification

Integration Empowers Hospitals to Streamline Patient Onboarding, Enhance Compliance, and Improve Care Delivery with Seamless…

8 hours ago

BLUE & CO., LLC PROVIDES NOTICE OF DATA EVENT

CARMEL, Ind., July 3, 2025 /PRNewswire/ -- Blue & Co., LLC ("Blue") is a financial…

11 hours ago

Dr. Aubrey de Grey Brings Cutting-Edge Science to RAADfest 2025: LEV Foundation Partners with Coalition for Radical Life Extension

Renowned biogerontologist Dr. Aubrey de Grey to curate specialized scientific programming at world's leading longevity…

11 hours ago

NervGen Strengthens Board Leadership to Accelerate Clinical and Corporate Growth

Dr. Adam Rogers appointed chair as company advances toward key milestones following positive topline chronic…

12 hours ago

ScienceSoft Raises the Bar for AI Voice Scheduling in Healthcare

MCKINNEY, Texas--(BUSINESS WIRE)--#AI--Human-Like, Real-Time AI Scheduler launched by ScienceSoft ScienceSoft has introduced a HIPAA-compliant AI…

14 hours ago

New Podcast “Spreading the Good BUZZ” Hosted by Josh and Heidi Case Launches July 7th with Explosive Global Reach and a Mission to Transform Lives

Through Hope and Community in Recovery, Sober.Buzz along with @SoberBuzzToken on Instagram are Impacting and…

17 hours ago